Lymphoma Trial, Recruiting NCT07555210 Sponsor: Jessica Mezzanotte Sharpe Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT07555210
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People with a known cancer diagnosis who are about to start, or have started within the last four weeks, a type of immunotherapy called an anti-PD-1 immune checkpoint inhibitor — either on its own or combined with chemotherapy — with the goal of curing the cancer (the immunotherapy must be FDA-approved, not experimental)
  • People whose treating doctor estimates they have a life expectancy of at least 12 months

Who may not be able to join:

  • People whose treating doctor has determined they are not suitable for anti-PD-1 immunotherapy
  • People whose cancer has spread to other parts of the body (metastatic disease)
  • People who are planned to receive two different immune checkpoint inhibitor therapies at the same time
  • People who have bone fractures in the pelvis, both hips or thigh bones, or the mid-to-lower spine
  • People who have been diagnosed with osteoporosis or osteopenia (conditions affecting bone density)
  • People who have received, or are planning to receive, certain bone-strengthening medications — including denosumab, zoledronic acid, or other bisphosphonates — within the last six months
  • People with parathyroid gland disorders, rheumatoid arthritis that is not well-controlled (or that requires ongoing biologic therapy or regular steroid use), advanced kidney disease (stage IV or V), or kidney failure requiring dialysis
  • People who would not be able to follow the study procedures as required
  • People who are unable to lie flat for 20 to 25 minutes during an imaging scan
  • People who are pregnant or breastfeeding
  • People with other medical or psychiatric conditions that, in the treating doctor's opinion, would prevent them from successfully taking part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 615-936-8422

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Jessica Mezzanotte Sharpe
Registry
ClinicalTrials.gov
Start date
25 August 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in BMD using DXA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov